DNV Capital

Cyrano Therapeutics, Inc., founded in 2014 and headquartered in Washington, D.C., develops therapeutic solutions aimed at addressing taste and smell disorders. The company's primary offering is an intranasal product, CYR-001, which repurposes the approved molecule Theophylline to restore sensory function in patients experiencing chronic loss of taste and smell. In preliminary studies, the treatment demonstrated significant efficacy, with eight out of ten patients showing notable improvements within two weeks and no reported side effects. In addition to the therapy, Cyrano Therapeutics provides a diagnostic kit to assess and quantify the severity of sensory loss, which can assist healthcare providers, particularly otolaryngologists, in managing care for affected individuals, including cancer patients undergoing chemotherapy who may experience sensory changes.

Chengdu Tianrui Xingtong Technology specializes in active phased array semiconductors and antennas for microwave and millimeter waves. Chengdu Tianruixingtong has been actively engaged in the field of millimeter wave-phased arrays. It has developed a number of mass-produced products and has extensive engineering experience in the production of phased array test equipment, modules, and antenna components.

Beijing Surgerii Technology Co., Ltd. specializes in the research, development, production, and sale of minimally invasive surgical robot systems in China. Founded in 2014 and based in Beijing, the company focuses on innovative technologies, particularly the next generation of flexible continuum robotic arms. Surgerii Technology aims to transform clinical practices through its single-hole and porous laparoscopic robot systems, enhancing the standard of care in minimally invasive surgeries. With a commitment to independent research and development, the company leverages its expertise in system design and integration to advance the medical equipment industry in China.

Sanoculis is a medical device start-up based in Tel Aviv, Israel, focused on developing innovative solutions for glaucoma treatment. The company has created a Minimally Invasive Micro Sclerostomy (MIMS) procedure, which utilizes a single-patient-use sterile tool alongside a multi-use external machine. This technique involves the creation of a sclero-corneal drainage channel to effectively reduce intraocular pressure. MIMS is designed as a microfluidic full-thickness procedure, employing a cutting and drilling device to minimize trauma to surrounding tissue and decrease scar formation, ultimately facilitating the development of a long-lasting filtering bleb. Through this approach, Sanoculis aims to enhance outcomes for patients undergoing glaucoma surgery while reducing the risk of complications.

Sinovation Medical specializes in the development of advanced medical robotic technology and innovative medical products. The company is dedicated to enhancing precision in healthcare through its surgical robots, which integrate clinical computer vision technology. These robots are primarily utilized in neurosurgery, addressing conditions such as epilepsy, Parkinson's disease, cerebral hemorrhage, and intracranial tumors. By providing reliable medical robotics, Sinovation aims to improve care for patients and support medical professionals in delivering effective treatments.

Wuhan Binhui Biotechnology Co., Ltd., established in 2010 and headquartered in Wuhan, China, specializes in the development of virus injection preparations. Situated in the Optics Valley Bio City within the Donghu National Independent Innovation Demonstration Zone, the company focuses on creating innovative products and services in the oncology sector, encompassing both diagnosis and treatment. Binhui Biotech is dedicated to developing offerings with independent intellectual property rights, aiming to compete effectively on the international market.

CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.

Hinova Pharma is an innovative drug research and development manufacturer that provides users with compound HC-1119 androgen receptor (AR) antagonism by using drug discovery systems such as medicinal chemistry, biological screening, process research, quality research, clinical reporting, and clinical research. Drugs, HC-1102 androgen receptor inhibitors and other products, for the treatment of advanced prostate cancer and breast cancer.

Geneseeq Technology Inc., established in 2008 and based in Toronto, Canada, operates a clinical testing and diagnostic center specializing in next-generation sequencing (NGS) technologies. The company focuses on advancing precision medicine in cancer treatment by transforming patients' genomic information into actionable insights for healthcare providers. Geneseeq's laboratories have attained significant certifications, including those from China's National Center of Clinical Laboratories and the College of American Pathologists, ensuring high standards in clinical diagnostics. The company offers a range of personalized medical diagnostics and healthcare management services, including genetic screening and molecular diagnostics, aimed at enhancing the detection and treatment success of cancer.

Sonendo, Inc. is a medical technology company based in Laguna Hills, California, specializing in innovative solutions for root canal therapy. Founded in 2006, the company has developed the GentleWave System, a technology platform that enhances the cleaning and disinfection of tooth structures without compromising integrity. This system significantly improves clinical outcomes and practice efficiency compared to traditional root canal methods. In addition to its product offerings, Sonendo is the parent company of TDO Software, which provides widely used practice management software for endodontic professionals. The software integrates various functionalities, including imaging and communication tools, to streamline practice workflows. Through its focus on advanced dental technologies, Sonendo aims to address the global challenge of tooth decay, ultimately promoting better dental health.

JFK Biotech develops products for molecular diagnosis and rapid self-test technology. They also offer a series of products for early screening, early diagnosis, and early treatment of pulmonary nodules, lung cancer, COPD, asthma, airway inflammation, and airway infection.

Angioslide, Ltd. is a medical device company established in 2005 and headquartered in Natanya, Israel, with additional subsidiaries in Karlsruhe, Germany, and Edina, Minnesota. The company specializes in developing innovative angioplasty products, notably the Angioslide eXtra balloon catheter, which serves both as a stand-alone balloon for angioplasty and as a device for debris removal. Its proprietary Embolic Capture Angioplasty™ technology allows physicians to capture and eliminate embolic particles, chronic thrombus, and atherosclerotic plaque debris during angioplasty procedures. Angioslide focuses on addressing the needs of various markets, including peripheral artery, lower limb artery, carotid, and coronary artery diseases.

Human Xtensions Ltd. is a company based in Netanya, Israel, specializing in the development of handheld digital solutions for minimally invasive surgery (MIS). Founded in 2012 by Moti Sholev, the company focuses on creating unmediated surgical systems that enhance surgical precision and ergonomics. Its flagship product, HandX, is a lightweight, handheld medical device that allows surgeons to translate their natural hand motions into intricate movements within the patient's body. By integrating the advantages of robotics with the ease of handheld tools, Human Xtensions aims to improve surgical outcomes and streamline the surgical process.

TruTag Technologies, Inc. specializes in precision-fabricated nano-porous silica for applications in drug delivery, product authentication, and data intelligence. The company has developed TruTag, an edible microtag that enables the identification and quality assurance of various products, including medicines, food items, and consumer goods. This technology is instrumental in combating counterfeiting, managing product diversions, and enhancing quality control across industries such as healthcare, life sciences, and food and beverages. TruTag Technologies operates a state-of-the-art cGMP manufacturing facility in Hawaii and maintains engineering and business development offices in California, Pennsylvania, Florida, Massachusetts, and Scotland. The company has been recognized for its innovative contributions, receiving accolades from organizations such as the SPIE Prism Awards and the World Economic Forum.

Vessix Vascular, Inc., previously known as Minnow Medical, Inc., is a privately-held company focused on developing innovative medical devices using radiofrequency balloon catheter technology. The company's primary product, the ZCath® System, has received a CE Mark, allowing its use in reducing plaque in peripheral leg arteries. Additionally, Vessix Vascular is working on a catheter-based device aimed at treating high blood pressure by targeting and deadening nerves near the kidneys. As a pre-revenue stage enterprise, Vessix Vascular is positioned to address significant medical needs in vascular health and hypertension management.